Abstract Submission

1. Language: English.
2. Title, Affiliation, Name, Abstract (Please prepare your data in this order)
3. The title of abstract must be within 200 characters including spaces.
4. The body of abstract should NOT exceed 1,100 characters including spaces.
5. Tables and images are NOT allowed.
6. Abstract Structure: Purpose-Methods-Results-Conclusions

*After submitting the abstract, you will receive an E-mail confirming the receipt of your abstract within 3 days. If you do not receive this e-mail, please contact the secretariat office. (63jspaci@cs-oto.com)

• Each initial letter of the name or title should be capitalized, and other letters should be in lowercase. Please do not omit words and phrases.
• Submissions for I-PAS session must be submitted by e-mail. Please click on "Submission Form" below.
• First authors should be the presenting author and should handle all communication with the secretariat.
• First author's full name, country, name of the institution, telephone number and e-mail address should be filled in the abstract submission form.
• First authors from overseas are required to submit CV and Letter of recommendation from your coach or trainer in English.

Please select a topic which is most applicable to your study. Accepted abstracts should be orally presented in English at I-PAS session on site.
Please note that the organizing committee of the 63rd Annual Meeting of Japanese Society of Pediatric Allergy and Clinical Immunology will make the final decision if the abstract is accepted.

01	Atopy: Prediction and prevention	02	Allergy march
03	Atopic dermatitis	04	Urticaria and angioedema
05	Asthma: Diagnosis	06	Asthma: Treatment
07	Rhinitis and sinusitis	08	Food allergy: Diagnosis
09	Food allergy: Treatment	10	Anaphylaxis
11	Adverse reaction to drugs	12	Allergy diagnosis (in vitro and in vivo)
13	Environment: Indoor and outdoor	14	Immunotherapy
15	Pharmacotherapy	16	Patient Education
17	Allergen	18	IgE
19	BHR and lung function etc	20	Genetics and pharmacogenetics
21	Mediators and antagonists	22	Cells involved in allergic diseases
23	Cytokines and chemokines	24	Immunodeficiency disorders
25	Immunity	26	Clinical immunology and autoimmune disorders
27	Airway disease	28	Upper and lower airway infection
29	Animal model of disease	30	Others

Abstracts will be reviewed and selected by the organizing committee of the　63rd Annual Meeting of Japanese Society of Pediatric Allergy and Clinical Immunology. Authors will be notified of selection by e-mail in June, 2026.

Abstract modification is possible until submission deadline. If you have to withdraw the abstract after the deadline, please inform the secretariat by E-mail by June 30, 2026.

Accepted abstracts will be published in the Nihon Shoni Arerugi Gakkaishi(The Japanese Journal of Pediatric Allergy and Clinical Immunology).

1. The abstract must be based on scientific evidence and be consistent with the content of the abstract.
2. The abstract presentation is not intended for commercial use.
3. COI status must be disclosed in accordance with the "Common Guidelines on Conflict of Interest (COI) in Medical Research" and its detailed regulations.
4. The authors are responsible for giving sufficient consideration to the protection of privacy.
5. The study reported in the abstract involved human subjects and it meets the ethical principles of the Declaration of Helsinki.
6. With the exception of case reports of less than five cases, the abstract of human research must be been approved by the Ethics Review Committee or IRB (Investigational Review Board) of each institution.
7. The abstract involved animal experiments must meet the relevant guidelines for the care and use of laboratory animals.

Please note that if there is any doubt about the content of your presentation after the fact, you may be asked to submit an approval document.

All authors are required to disclose any financial relationship within the past 3 years with a biotechnology manufacturer, a pharmaceutical company, or other commercial entities that have an interest in the subject matter or materials discussed in the abstract and presentation. The matters requiring disclosure are outlined in the JSPACI Conflict of Interest Policy.
The details of COI declaration in the presentation slides will be informed on the congress website.

1. Employment/Leadership position/Advisory role
   (1,000,000 yen or more from one commercial entity)
2. Stock ownership or options
   (Profit of 1,000,000 yen or more from one commercial entity / ownership of 5% or more of total shares of one company)
3. Patent royalties/licensing fees
   (1,000,000 yen or more per one royalty/licensing fee)
4. Honoraria (e.g. lecture fees)
   (500,000yen or more annually from one commercial entity)
5. Fees for promotional materials (e.g. Manuscript fees)
   (500,000yen or more from one commercial entity)
6. Research funding
   (1,000,000 yen or more from one commercial entity)
7. Scholarship donation
   (1,000,000 yen or more from one commercial entity)
8. Endowed departments by commercial entities
   (If any of the authors belongs to an endowed department sponsored by any commercial entity)
9. Others (e.g. trips, travel, or gifts, that are not related to research)
   (50,000 yen or more from one commercial entity)

*Please refer to the current currency exchange rate for Japanese Yen at an appropriate website.

Please register using the submission form below.
The participation fee must be paid in advance and refunded at the venue on the day of the event.

Secretariat Office of the 63rd Annual Meeting of Japanese Society of Pediatric Allergy and Clinical Immunology
E-mail: 63jspaci@cs-oto.com